Inmune Bio, Inc.
INMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001711754
No open-market purchases or sales by Inmune Bio, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $7.08M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Inmune Bio, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 43 | 34 | −9 |
| Shares | 2.49M | 2.30M | −190.0K (−7.6%) |
| Value | $25.4M | $19.3M | −$6.03M (−23.8%) |
New holders (1)
Institutions that held Inmune Bio, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cordasco Financial Network | 100 | $1.00K | 0.00% |
Sold out (10)
Institutions that held Inmune Bio, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Millennium Management LLC | 150,680 | $1.54M |
| Virtu Financial LLC | 24,364 | $249.0K |
| Jump Financial, LLC | 21,100 | $215.0K |
| Goldman Sachs Group Inc | 20,053 | $205.0K |
| Jane Street Group, LLC | 17,098 | $175.0K |
| Walleye Capital LLC | 17,127 | $175.0K |
| Susquehanna Fundamental Investments, LLC | 12,473 | $127.0K |
| Dimensional Fund Advisors LP | 11,052 | $113.0K |
| Tower Research Capital LLC (TRC) | 7,306 | $75.0K |
| Migdal Insurance & Financial Holdings Ltd. | 1,003 | $10.0K |